{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:13:19Z","timestamp":1789150399840,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["72274008\/72304006"],"award-info":[{"award-number":["72274008\/72304006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["72274008\/72304006"],"award-info":[{"award-number":["72274008\/72304006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Natural Science Foundation","award":["9232010"],"award-info":[{"award-number":["9232010"]}]},{"name":"Beijing Natural Science Foundation","award":["9232010"],"award-info":[{"award-number":["9232010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Health Popul Nutr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Tyrosine kinase inhibitors (TKIs) have been shown to improve survival rate in chronic myeloid leukemia (CML) patients, but their high costs impose a significant economic burden. This study aimed to evaluate the impact of China\u2019s National Volume-Based Procurement (NVBP) policy on the affordability, procurement volume, and costs of these drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Based on the data of drug procurement transactions in the database of China Health Insurance Bureau, this study analyzed the impact of National Volume-Based Procurement policy on the affordability, Defined Daily Doses (DDDs), expenditure, and Defined Daily Dose cost (DDDc) of three tyrosine kinase inhibitor (Imatinib, Nilotinib, and Dasatinib) in 25 provinces and hospitals of different levels from January 2019 to December 2020 in China by using an interrupted time series model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>After the implementation of the procurement policy, the unit price of policy-related Imatinib decreased, leading to increased affordability and a rise of 146.9 thousand DDDs in the month of implementation (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), while expenditure remained unchanged. The DDDs and expenditures for Nilotinib and Dasatinib did not show significant changes. The procurement volume of bid-winning generic Imatinib increased by 215.2 thousand DDDs in the month of policy implementation (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), with usage share rising from approximately 40% to 80%. Conversely, the DDDs of non-bidding generic and originator drugs significantly decreased post-implementation. The DDDc of Imatinib reduced 69.5 in the month of NVBP implementation (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Furthermore, the DDDc of both bid-winning generic and non-bidding generic Imatinib significantly decreased in the month of policy implementation (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The National Volume-Based Procurement policy effectively reduced the unit price of relevant drugs and increased their utilization, thereby improving drug affordability and reducing the financial burden on CML patients requiring long-term treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41043-025-00829-y","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:41:24Z","timestamp":1744285284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of national volume-based procurement policy on drugs treating chronic Myelogenous Leukemia"],"prefix":"10.1186","volume":"44","author":[{"given":"Zhao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"issue":"8","key":"829_CR1","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jama.286.8.895","volume":"286","author":"M Kalidas","year":"2001","unstructured":"Kalidas M, Kantarjian H, Talpaz M. Chronic myelogenous leukemia. JAMA. 2001;286(8):895\u20138.","journal-title":"JAMA"},{"issue":"1","key":"829_CR2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.6004\/jnccn.2012.0009","volume":"10","author":"S O\u2019Brien","year":"2012","unstructured":"O\u2019Brien S, Abboud CN, Akhtari M, Altman J, Berman E, DeAngelo DJ, et al. Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2012;10(1):64\u2013110.","journal-title":"J Natl Compr Canc Netw."},{"issue":"10314","key":"829_CR3","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","volume":"398","author":"J Cortes","year":"2021","unstructured":"Cortes J, Pavlovsky C, Sau\u00dfele S. Chronic myeloid leukaemia. Lancet. 2021;398(10314):1914\u201326.","journal-title":"Lancet"},{"key":"829_CR4","unstructured":"National health commission of the people\u2019s republic of china. Diagnosis and treatment guidelines for chronic myeloid leukemia (2022 Edition) [in Chinese] 2022 [updated April 11, 2022. Available from: http:\/\/www.nhc.gov.cn\/yzygj\/s7659\/202204\/a0e67177df1f439898683e1333957c74.shtml."},{"key":"829_CR5","unstructured":"Chinese Medical Association. The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition) [in Chinese]. Zhonghua xue ye xue za zhi= Zhonghua Xueyexue Zazhi. 2020;41(5):353\u201364."},{"issue":"10","key":"829_CR6","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","volume":"18","author":"MW Deininger","year":"2020","unstructured":"Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, et al. Chronic myeloid leukemia, version 22021, NCCN clinical practice guidelines in oncology. J Natl Compreh Cancer Netw. 2020;18(10):1385\u2013415.","journal-title":"J Natl Compreh Cancer Netw."},{"issue":"4","key":"829_CR7","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384.","journal-title":"Leukemia"},{"issue":"3","key":"829_CR8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","volume":"14","author":"G Rosti","year":"2017","unstructured":"Rosti G, Castagnetti F, Gugliotta G, Baccarani M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol. 2017;14(3):141\u201354.","journal-title":"Nat Rev Clin Oncol."},{"issue":"42","key":"829_CR9","doi-asserted-by":"crossref","first-page":"68442","DOI":"10.18632\/oncotarget.12035","volume":"7","author":"J Xu","year":"2016","unstructured":"Xu J, Zhang X, Yang H, Ding G, Jin B, Lou Y, et al. Comparison of outcomes of tyrosine kinase inhibitor in first-or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations. Oncotarget. 2016;7(42):68442.","journal-title":"Oncotarget"},{"issue":"42","key":"829_CR10","doi-asserted-by":"crossref","first-page":"71548","DOI":"10.18632\/oncotarget.17742","volume":"8","author":"DA Goldstein","year":"2017","unstructured":"Goldstein DA, Clark J, Tu Y, Zhang J, Fang F, Goldstein R, et al. A global comparison of the cost of patented cancer drugs in relation to global differences in wealth. Oncotarget. 2017;8(42):71548.","journal-title":"Oncotarget"},{"issue":"15","key":"829_CR11","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/cncr.32137","volume":"125","author":"KM Kenzik","year":"2019","unstructured":"Kenzik KM, Bhatia R, Williams GR, Bhatia S. Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia. Cancer. 2019;125(15):2570\u20138.","journal-title":"Cancer"},{"key":"829_CR12","unstructured":"IQVIA. Global Oncology Trends 2023 2023 [updated May 24, 2023. Available from: https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/global-oncology-trends-2023. ."},{"key":"829_CR13","unstructured":"Norwegian Institute of Public Health. ATC\/DDD Index 2024 2024 [updated January 26, 2024. Available from: https:\/\/atcddd.fhi.no\/atc_ddd_index\/."},{"key":"829_CR14","unstructured":"World Health Organization. Measuring medicine prices, availability, affordability and price components (2nd Ed.) 2016 [updated May 2016. Available from: https:\/\/haiweb.org\/media-resource\/measuring-medicine-prices-availability-affordability-and-price-components-2nd-ed\/."},{"issue":"3","key":"829_CR15","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1200\/OP.20.00143","volume":"17","author":"JJ Wilkes","year":"2021","unstructured":"Wilkes JJ, Lyman GH, Doody DR, Chennupati S, Becker LK, Morin PE, et al. Health care cost associated with contemporary chronic myelogenous leukemia therapy compared with that of other hematologic malignancies. JCO Oncol Pract. 2021;17(3):e406\u201315.","journal-title":"JCO Oncol Pract."},{"issue":"9","key":"829_CR16","doi-asserted-by":"crossref","first-page":"e005519","DOI":"10.1136\/bmjgh-2021-005519","volume":"6","author":"J Yuan","year":"2021","unstructured":"Yuan J, Lu ZK, Xiong X, Jiang B. Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China. BMJ Glob Health. 2021;6(9):e005519.","journal-title":"BMJ Glob Health"},{"key":"829_CR17","doi-asserted-by":"crossref","first-page":"944540","DOI":"10.3389\/fphar.2022.944540","volume":"13","author":"H Long","year":"2022","unstructured":"Long H, Yang Y, Geng X, Mao Z, Mao Z. Changing characteristics of pharmaceutical prices in China under centralized procurement policy: a multi-intervention interrupted time series. Front Pharmacol. 2022;13:944540.","journal-title":"Front Pharmacol."},{"issue":"7","key":"829_CR18","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1377\/hlthaff.2019.01122","volume":"39","author":"VD Lauenroth","year":"2020","unstructured":"Lauenroth VD, Kesselheim AS, Sarpatwari A, Stern AD. Lessons from the impact of price regulation on the pricing of anticancer drugs in Germany: study assesses the effects of female political representation on mortality among children younger than age five in Brazil. Health Aff. 2020;39(7):1185\u201393.","journal-title":"Health Aff."},{"issue":"6","key":"829_CR19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.healthpol.2019.03.009","volume":"123","author":"F Villa","year":"2019","unstructured":"Villa F, Tutone M, Altamura G, Antignani S, Cangini A, Fortino I, et al. Determinants of price negotiations for new drugs. The experience of the Italian medicines agency. Health Policy. 2019;123(6):595\u2013600.","journal-title":"Health Policy"},{"key":"829_CR20","first-page":"15444","volume":"368","author":"A Ferrario","year":"2020","unstructured":"Ferrario A, Dedet G, Humbert T, Vogler S, Suleman F, Pedersen HB. Strategies to achieve fairer prices for generic and biosimilar medicines. BMJ. 2020;368:15444.","journal-title":"BMJ"},{"key":"829_CR21","doi-asserted-by":"crossref","first-page":"804237","DOI":"10.3389\/fphar.2021.804237","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Ji X, Xiao H, Unger JM, Cai Y, Mao Z, et al. Impact of the pilot volume-based drug purchasing policy in China: Interrupted time-series analysis with controls. Front Pharmacol. 2021;12:804237.","journal-title":"Front Pharmacol."},{"key":"829_CR22","doi-asserted-by":"crossref","first-page":"714127","DOI":"10.3389\/fpubh.2021.714127","volume":"9","author":"W Fang","year":"2021","unstructured":"Fang W, Xu X, Zhu Y, Dai H, Shang L, Li X. Impact of the national health insurance coverage policy on the utilisation and accessibility of innovative anti-cancer medicines in China: an interrupted time-series study. Front Public Health. 2021;9:714127.","journal-title":"Front Public Health"}],"container-title":["Journal of Health, Population and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41043-025-00829-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41043-025-00829-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41043-025-00829-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T12:53:59Z","timestamp":1744289639000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhpn.biomedcentral.com\/articles\/10.1186\/s41043-025-00829-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["829"],"URL":"https:\/\/doi.org\/10.1186\/s41043-025-00829-y","relation":{},"ISSN":["2072-1315"],"issn-type":[{"value":"2072-1315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"14 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve patient or public participation and therefore did not require an ethical statement or patient informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}